Stage II-IV Ovarian or Primary Peritoneal Cancer: Treatment with Letrozole with or
without Paclitaxel and Carboplatin
How well does letrozole - with or without paclitaxel and carboplatin - work in treating
patients with stage II-IV low-grade serous carcinoma of the ovary or peritoneum?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin
works in treating patients with stage II-IV low-grade serous carcinoma of the ovary
or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen
made by the body which in turn may stop the growth of tumor cells that need estrogen
to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them
from dividing, or by stopping them from spreading. It is not yet known whether giving
letrozole alone or in combination with paclitaxel and carboplatin works better in
treating patients with low-grade serous carcinoma of the ovary or peritoneum compared
to paclitaxel and carboplatin without letrozole.
Study Reference #: CGYM19142
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Laura Mitchell
Phone: (585) 275-7763
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search